A Plus Biotechnology CoTPE:6918 -1.59%71 EV-to-FCF is 13.91 as of Jul. 08, 2026, which is 19% below its 10-year median of 17.11. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 416 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 74.28% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, A Plus Biotechnology Co's Enterprise Value is NT$2,021.0 Mil.
A Plus Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$145.3 Mil. Therefore, A Plus Biotechnology Co's EV-to-FCF for today is 13.91.
The historical rank and industry rank for A Plus Biotechnology Co's EV-to-FCF or its related term are showing as below:
TPE:6918'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.67 Med: 17.11 Max: 102.92
Current: 13.72
During the past 7 years, the highest EV-to-FCF of A Plus Biotechnology Co was 102.92. The lowest was 13.67. And the median was 17.11.
TPE:6918's EV-to-FCF is ranked better than 74.28% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.515
vs TPE:6918: 13.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
A Plus Biotechnology Co (TPE:6918) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
A Plus Biotechnology Co's PE Ratio (TTM) for today is calculated as:
A Plus Biotechnology Co's share price for today is NT$74.30.
A Plus Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's EV-to-FCF falls into.
A Plus Biotechnology Co's current Enterprise Value is NT$2,021.0 Mil.
A Plus Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$145.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a EV-to-FCF of 13.91 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on A Plus Biotechnology Co and its competitors. This is 19% below median its historical median of 17.11. Over the past decade, A Plus Biotechnology Co's EV-to-FCF has ranged from 13.67 to 102.92. According to the industry distribution chart, A Plus Biotechnology Co ranks #107 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 25.7%.
Is A Plus Biotechnology Co's EV-to-FCF too high?
A Plus Biotechnology Co's current EV-to-FCF of 13.91 is 19% below median its 10-year median of 17.11. Over the past 10 years, this metric has ranged from a low of 13.67 to a high of 102.92. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. A Plus Biotechnology Co's value of 13.91 is 40.8% below this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #107 out of 416 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #107 out of 416 companies for EV-to-FCF. This puts A Plus Biotechnology Co in the upper half of its industry. The industry median EV-to-FCF is 23.52. A Plus Biotechnology Co's value of 13.91 is 40.8% below this benchmark. Historically, A Plus Biotechnology Co's own EV-to-FCF has ranged from 13.67 to 102.92 over the past decade. While the company's 10-year median is 17.11 vs. the industry median of 23.52, A Plus Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current EV-to-FCF of 13.91 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current EV-to-FCF is 13.91, which is 19% below median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current EV-to-FCF is 13.91, which is 19% below median its 10-year median of 17.11 and 40.8% below the Medical Devices & Instruments industry median of 23.52. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current EV-to-FCF is 13.91 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
EV-to-FCF: 13.91 (19% below median its 10-year median of 17.11)
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
Industry Position: 40.8% below the Medical Devices & Instruments median (#107 of 416)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
